

**OFFICIAL**

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**RECEIVED  
CENTRAL FAX CENTER****MAR 11 2004**

**To:** Customer Service Center  
**Fax Number:** (703) 872-9306


**Attn:** Examiner Konata M. George      Group Art Unit: 1616

**From:** Brian L. Buckwalter  
Roche Palo Alto LLC,  
3431 Hillview Ave., Palo Alto, CA  
Return Fax No.: 650/ 855-5322

**Total Pages:** 7 (including cover page)

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that the correspondence cited below is being facsimile transmitted to the Patent and Trademark Office on March 11, 2004.

  
Chris Myers

[Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.]

**Documents Attached:**

For: S/N 09/966,202, filed September 26, 2001, Docket No. R0086B-DIV  
inventor Paula N. Belloni

1. Response to Notice of Non-Compliant Amendment, 6 pages

Doc 123999

U.S. Serial No. 09/966,202

Attorney Docket R0086B-DIV

RECEIVED  
CENTRAL FAX CENTER

MAR 11 2004

OFFICIAL

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Address to:</b> Commissioner for Patents PO Box 1450 Alexandria, VA 22313  <b>FAX to:</b> 703-872-9306	<b>First Inventor.</b>	Belloni, Paula N.
	<b>Application Number</b>	09/966,202
	<b>Filing Date</b>	09/26/2001
	<b>Group Art Unit</b>	1616
	<b>Examiner</b>	George, Konata M.
	<b>Attorney Docket No.</b>	R0086B-DIV
	<b>Title:</b>	METHODS FOR THE TREATMENT OF EMPHYSEMA USING 13-CIS RETINOIC ACID

Honorable Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

**RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT**

This Paper responds to the Office Action dated February 26, 2004 with a shortened statutory period for response set to expire May 26, 2004.

A listing of the claims begins on page 2 of this paper.

Remarks begin on page 6 of this paper.